Cas:641615-34-1 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one manufacturer & supplier

Chemical Name:3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one

CAS.NO:641615-34-1

Synonyms:3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one

Molecular Formula:C₉H₁₁N₃O

Molecular Weight:177.20300

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:291.1ºC at 760 mmHg

Density:1.122g/cm3

Index of Refraction:1.548

PSA:46.09000

Exact Mass:177.09000

LogP:0.73460

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one Use and application,3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one technical grade,usp/ep/jp grade.

Related News: The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one manufacturer Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies. 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one supplier Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one vendor Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. 3-(dimethylamino)-1-pyrimidin-5-ylprop-2-en-1-one factory Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection.